$HALO insider trading
Over the last 12 months, Halozyme Therapeutics insiders reported no purchases and 32 sales totaling $42.4M across SEC Form 4 filings. 94% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $42.4M 32 events
- Events · 12m
- 32 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 94% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Posard Matthew L.D | ▼ Sale | 18,996 | $107.74 | $2.0M | -24.4% | plan · 4 tranches |
| Sep 11, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 60,000 | $107.28 | $6.4M | -7.2% | plan · 7 tranches |
| Aug 19, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 60,000 | $104.59 | $6.3M | -7.2% | plan · 11 tranches |
| Aug 10, 2026 | Connaughton BernadetteD | ▼ Sale | 1,626 | $102.8 | $167K | -3.9% | plan |
| Jul 8, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 1,923 | $79.77 | $153K | -0.2% | plan · 2 tranches |
| Jul 1, 2026 | Connaughton BernadetteD | ▼ Sale | 1,625 | $76.71 | $125K | -3.7% | plan · 2 tranches |
| Jun 29, 2026 | Krishnan MaheshD | ▼ Sale | 7,304 | $75 | $548K | -33.6% | plan |
| Jun 3, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 6,100 | $69.69 | $425K | -0.8% | plan |
| Jun 3, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 2,000 | $68.74 | $137K | -0.3% | plan |
| Jun 3, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 1,500 | $67.68 | $102K | -0.2% | plan |
| Jun 3, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 400 | $66.37 | $27K | -0.1% | plan |
| Jun 2, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 3,400 | $66.74 | $227K | -0.4% | plan |
| Jun 2, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 16,600 | $66.31 | $1.1M | -2.1% | plan |
| Jun 1, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 5,401 | $68.35 | $369K | -0.7% | plan |
| Jun 1, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 12,989 | $67.41 | $876K | -1.7% | plan |
| Jun 1, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 1,610 | $66.39 | $107K | -0.2% | plan |
| Jun 1, 2026 | Connaughton BernadetteD | ▼ Sale | 1,625 | $66.21 | $108K | -3.6% | plan |
| May 1, 2026 | Connaughton BernadetteD | ▼ Sale | 1,625 | $63.48 | $103K | -4.1% | plan |
| Apr 6, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 10,000 | $63.5 | $635K | -1.3% | plan · 2 tranches |
| Apr 2, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 40,000 | $64.81 | $2.6M | -5% | plan · 4 tranches |
| Mar 10, 2026 | Caudill CortneySVP, CHIEF OPERATING OFFICER · O | ▼ Sale | 28,857 | $67.75 | $2.0M | -80.4% | 3 tranches |
| Mar 4, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 50,000 | $69.52 | $3.5M | -6.1% | plan · 7 tranches |
| Feb 5, 2026 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 50,000 | $77.07 | $3.9M | -6.6% | plan · 7 tranches |
| Jan 5, 2026 | Connaughton BernadetteD | ▼ Sale | 2,000 | $70.25 | $141K | -4.7% | plan |
| Dec 1, 2025 | Connaughton BernadetteD | ▼ Sale | 829 | $71.6 | $59K | -1.9% | plan |
| Dec 1, 2025 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 16,569 | $68.92 | $1.1M | -2.3% | plan · 4 tranches |
| Nov 12, 2025 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 60,000 | $69.47 | $4.2M | -7.6% | plan · 8 tranches |
| Nov 10, 2025 | Connaughton BernadetteD | ▼ Sale | 2,000 | $68.48 | $137K | -4.4% | plan |
| Nov 1, 2025 | Caudill CortneySVP, CHIEF OPERATING OFFICER · O | ▼ Sale | 4,263 | $65.19 | $278K | -25.1% | late |
| Oct 3, 2025 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 60,000 | $71.86 | $4.3M | -7.6% | plan · 11 tranches |
| Oct 1, 2025 | Connaughton BernadetteD | ▼ Sale | 2,000 | $75.24 | $150K | -4.3% | plan · 2 tranches |
| Sep 22, 2025 | LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER · O | ▼ Sale | 2,227 | $77.95 | $174K | -9.2% | plan · 2 tranches |
| Sep 10, 2025 | LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER · O | ▼ Sale | 20,000 | $75.71 | $1.5M | -45.1% | plan · 2 tranches |
| Sep 4, 2025 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 60,000 | $74.08 | $4.4M | -7.6% | plan · 8 tranches |
| Sep 2, 2025 | Connaughton BernadetteD | ▼ Sale | 4,000 | $73.68 | $295K | -7.9% | plan · 3 tranches |
| Aug 13, 2025 | Torley HelenPRESIDENT AND CEO · O·D | ▼ Sale | 60,000 | $63.62 | $3.8M | -7.6% | plan · 6 tranches |
Every $HALO filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Halozyme Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $HALO feed.